MAIA Biotechnology (MAIA) Projected to Post Earnings on Friday

MAIA Biotechnology (NYSEAMERICAN:MAIA) is projected to post its Q4 2025 results before the market opens on Friday, March 20th. Analysts expect MAIA Biotechnology to post earnings of ($0.13) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

MAIA Biotechnology Stock Down 0.7%

Shares of MAIA opened at $1.49 on Thursday. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19. The business’s fifty day moving average is $1.94 and its 200 day moving average is $1.58. The stock has a market cap of $57.60 million, a P/E ratio of -2.04 and a beta of -0.04.

Insiders Place Their Bets

In other MAIA Biotechnology news, Director Stan Smith acquired 57,189 shares of the stock in a transaction on Monday, December 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $69,770.58. Following the completion of the acquisition, the director owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. This represents a 4.19% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Steven M. Chaouki acquired 40,849 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The shares were acquired at an average price of $1.22 per share, with a total value of $49,835.78. Following the completion of the acquisition, the director directly owned 151,873 shares of the company’s stock, valued at approximately $185,285.06. The trade was a 36.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 179,737 shares of company stock worth $219,279. Insiders own 32.32% of the company’s stock.

Institutional Trading of MAIA Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology in the second quarter worth approximately $29,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $52,000. Finally, Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares during the last quarter. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.